Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beraprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.85 |
| ▸ | PTGER3 | P43115 | 13/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGFR | P43088 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beraprost SCHEMBL4754472 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL11946708 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16904620 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL4754473 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16405382 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL6084946 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16894023 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL22972690 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL21778834 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL19113984 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015109112-A1 | COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS | GEMMUS PHARMA INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2011057262-A2 | TREATMENT OF INFECTIONS WITH TP RECEPTOR ANTAGONISTS | EVOLVA INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-0742011-B1 | PERCUTANEOUSLY ABSORBABLE PREPARATION | TORAY INDUSTRIES (JP) | 2002-07-24 | — | — | EP | claimed |
| EP-1043030-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | claimed |
| EP-4620525-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12263174-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-11491161-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11491160-B2 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | Respira Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220347183-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220079949-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2022-03-17 | — | — | US | disclosed |
| US-6919372-B1 | Sustained release pharmaceutical compositions | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20030013898-A1 | Pericyte protective agent | TORAY INDUSTRIES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6328979-B1 | Sustained release medicinal compositions | YAMANOUCHI PHARMACEUTICALS, CO. LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1043030-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043031-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-0583482-B1 | REMEDY FOR WOUND OR HEMORRHOID | KAKEN PHARMA CO LTD (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0742011-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATION | TORAY INDUSTRIES, INC. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0583482-A1 | REMEDY FOR WOUND OR HEMORRHOID | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1994-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | PTGIR 3210/4885PTGER3 4050/4885PTGER2 4530/4885 |
| US-20030013898-A1 | Pericyte protective agent | PGF, PTGIR, PDGFA | PTGIR 2/4885PTGER3 19/4885PTGER2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.